Mabwell (Shanghai) Bioscience (688062) Fundamentals 2026 — Revenue Analysis | SniperIQ
Mabwell (Shanghai) Bioscience (688062) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥13.5B, trading at ¥33.69 on the SHH. This SniperIQ fundamentals page covers Mabwell (Shanghai) Bioscience's valuation, profitability (net margin -123.5%), revenue (¥663M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mabwell (Shanghai) Bioscience's market cap?
Mabwell (Shanghai) Bioscience (688062) has a market capitalization of approximately ¥13.5B, trading at ¥33.69 on the SHH. Market cap moves with the live share price.
What is Mabwell (Shanghai) Bioscience's P/E ratio?
Mabwell (Shanghai) Bioscience's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 125.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Mabwell (Shanghai) Bioscience?
Mabwell (Shanghai) Bioscience runs a net profit margin of -123.5%, a gross margin of 97.3%, and an operating margin of -117.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mabwell (Shanghai) Bioscience generate?
Mabwell (Shanghai) Bioscience reported revenue of ¥663M for fiscal year 2025, with net income of -¥970M and earnings per share (EPS) of -2.43. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mabwell (Shanghai) Bioscience pay a dividend?
Mabwell (Shanghai) Bioscience does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Mabwell (Shanghai) Bioscience financially healthy?
Mabwell (Shanghai) Bioscience carries a debt-to-equity ratio of 29.86x and a current ratio of 0.88x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mabwell (Shanghai) Bioscience a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mabwell (Shanghai) Bioscience (688062) the key facts are: market cap ¥13.5B, revenue ¥663M, 52-week range 25.13-63.59. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Mabwell (Shanghai) Bioscience's full fundamentals live
Get Mabwell (Shanghai) Bioscience's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.